X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ENT-03 is a novel, endogenous, centrally acting aminosterol with protein tyrosine phosphatase 1B (PTP1B) inhibitory activity, which normalizes glucose and causes weight loss by acting on brain circuits that regulate energy and metabolism in Obesity and Type 2 Diabetes.
Lead Product(s): ENT-03
Therapeutic Area: Endocrinology Product Name: ENT-03
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
Enterin’s oral lead compound, ENT-01 which prevents alpha synuclein from accumulating and aggregating within the enteric nervous system, receives FDA acceptance of an investigator sponsored IND application to treat a patient with prodromal multisystem atrophy.
Lead Product(s): Squalamine phosphate
Therapeutic Area: Neurology Product Name: ENT-01
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
ENT-01 is administered orally and acts locally on the ENS. It dislodges αS aggregates and inhibits their formation, restoring the firing potential of enteric neurons.
Lead Product(s): ENT-01
Therapeutic Area: Neurology Product Name: ENT-01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Parkinson’s Virtual Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 13, 2022
Details:
Enterin completed the first human clinical trials for ENT-01 which demonstrated that oral administration of its treatment has restored function of the nervous system of the gastrointestinal tract in Parkinson’s patients.
Lead Product(s): ENT-01
Therapeutic Area: Neurology Product Name: ENT-01
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Pfizer CentreOne
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 28, 2022
Details:
Dr. Denise Barbut, Enterin's co-founder and CMO, will present the company's latest updates relating to its lead compound, ENT-01, which is currently being developed for the treatment of Parkinson's Disease (PD).
Lead Product(s): ENT-01
Therapeutic Area: Neurology Product Name: ENT-01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2021
Details:
COV-ENT-1 has been shown to have broad-spectrum antiviral activity against both RNA and DNA viruses, both in vitro and in vivo, in studies supported by the NIAID.
Lead Product(s): COV-ENT-1
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
